诺和诺德表示其重磅减肥药Wegovy第二季度销售额同比飙升67%尽管有数百万美国患者正在使用该药的非品牌仿制药。这家丹麦

智通财经
Aug 06
诺和诺德表示其重磅减肥药Wegovy第二季度销售额同比飙升67%尽管有数百万美国患者正在使用该药的非品牌仿制药。这家丹麦公司上周大幅下调了全年业绩预期并警告称美国市场的减肥和糖尿病仿制药阻碍了其品牌治疗药物的销售这导致其股价直线跳水。美国的调制药房一直在生产诺和诺德的Ozempic和Wegovy的低成本仿制药这是美国食品药品监督管理局(FDA)允许的做法因为正品治疗药物供应短缺。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10